Trial · NCT00680992
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | Any TEAE | 260 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | Any TEAE | 231 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | Any TEAE | 12 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | Serious TEAE | 98 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | Serious TEAE | 39 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | Serious TEAE | 5 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | Fatal TEAE | 8 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | Fatal TEAE | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | Fatal TEAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | TEAE leading to treatment phase discontinuation | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | TEAE leading to treatment phase discontinuation | 24 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | TEAE leading to treatment phase discontinuation | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | TEAE leading to study drug discontinuation | 27 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | TEAE leading to study drug discontinuation | 23 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | TEAE leading to study drug discontinuation | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | CTCAE Grade 3, 4, or 5 | 121 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | CTCAE Grade 3, 4, or 5 | 59 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 3 (Denosumab 120 mg Q4W) | CTCAE Grade 3, 4, or 5 | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 1 (Denosumab 120 mg Q4W) | Any TEAE related to study drug | 184 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort 2 (Denosumab 120 mg Q4W) | Any TEAE related to study drug | 136 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00680992/results